SCP
VSTM icon

SymBiosis Capital Partners’s Verastem VSTM Stock Holding History

SymBiosis Capital Partners’s Portfolio VSTM Stock Details VSTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,000,000
Closed -$15.4M – 11
2025
Q4 		$15.4M Buy
+2,000,000
New +$17.8M 14.1% 2

Other funds holding VSTM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SymBiosis Capital Partners's VSTM Position: Q1 2026 in Review

SymBiosis Capital Partners sold out of Verastem (VSTM) in Q1 2026, closing a stake of 2,000,000 shares — an estimated $15.4M sold.

SymBiosis Capital Partners first reported a position in VSTM in Q4 2025 and held it in 1 quarter. The position peaked at $15.4M in Q4 2025. 155 funds tracked by Wall St. Rank hold VSTM as of Q1 2026.

  • SymBiosis Capital Partners reported no remaining Verastem position as of Q1 2026 after selling out during the quarter.
  • SymBiosis Capital Partners sold 2,000,000 Verastem shares in Q1 2026, an estimated $15.4M.
  • SymBiosis Capital Partners first reported a position in Verastem in Q4 2025 and held it in 1 quarter.
  • SymBiosis Capital Partners's Verastem position peaked at $15.4M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Verastem as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.